Market Definition and Introduction
The global mRNA synthesis & manufacturing market was valued at USD 859.4 million in 2024 and is anticipated to reach approximately USD 969.30 million by 2035, growing at a moderate CAGR of 1.1% during the forecast period (2025–2035). The landscape of pharmaceutical innovation has been reshaped by mRNA technology after the COVID-19 pandemic, with applications far beyond just vaccines against infectious diseases; as the industry matures, mRNA synthesis and manufacturing processes are refined and repurposed for next-generation cancer therapeutics, rare genetic disorders, and personalised immunotherapy solutions. Momentum built throughout the global vaccination drive underscored the need for robust, scalable, and high-fidelity mRNA manufacturing platforms that can support clinical-grade and commercial-grade development under strict regulatory scrutiny.
Research-grade mRNA strands to GMP-compliant large-scale production, companies are leveraging advanced enzymatic synthesis techniques, lipid nanoparticle formulation capabilities, and AI-driven optimisation protocols to compress timelines and reduce costs. With the result in end-to-end support from preclinical to commercial continuum sought by therapeutics and vaccine developers, reliable mRNA contract development and manufacturing organisations (CDMO) are increasingly becoming popular. This has thrown the door wide open to strategic partnerships and mergers aimed at accelerating market readiness and building biomanufacturing resilient capacity in the face of future health emergencies.
Industry is oriented to modular, flexible production models with plug-and-play bioreactor designs to adapt to a dynamic demand cycle. From pandemic-driven emergency production to precision medicine-oriented chronic care models, the infrastructure will need to be recalibrated and controls digitised, and evolving regulatory frameworks on nucleic acid-based therapies will need to be aligned along the way. The change will entice a low CAGR that the market faces as it enters into an inflexion point, as scale gives way to specialisation, and success will be dictated by scientific precision, compliance, agility, and manufacturing excellence.
Recent Developments in the Industry
In 2024, Moderna Inc. announced a multi-million-dollar expansion of its mRNA manufacturing facility in Norwood, Massachusetts, aiming to boost commercial-scale production capacity for its pipeline of respiratory and rare disease therapeutics. The expansion will also incorporate advanced digital analytics and AI-assisted batch validation systems.
In late 2023, BioNTech SE unveiled plans to deploy its BioNTainer manufacturing platforms in emerging markets, including Rwanda and Senegal. These modular, mobile manufacturing units are intended to support localised vaccine and mRNA therapeutic production, promoting regional autonomy and pandemic preparedness.
In 2023, Thermo Fisher Scientific acquired a specialist bioproduction facility focused on lipid nanoparticle formulation, a core component in mRNA drug delivery. The acquisition is poised to fortify Thermo Fisher’s capabilities as a key CDMO for mRNA vaccine and therapeutic developers seeking clinical and commercial support.
Market Dynamics
Demand for Personalised Therapy-fired Investments into mRNA Manufacturing
The worldwide development of personalised therapy has steepened the focus on scalable mRNA manufacturing solutions, as this molecule is easily adaptable to the specific profile of a disease, especially when treating oncology and rare genetic disorders. Pharma companies increasingly look toward individualised medicine, and soon after started demanding custom synthesis capabilities. This necessitates integrated bioprocessing platforms that can provide short lead times and moderate accuracy in transcript design to forge ahead toward the next impact of tailored therapeutic options.
Technological Advances Affirm an Evolution in the Market
Continuous innovation in in-vitro transcription chemistry, enzymatic optimisation, and digital biomanufacturing has bolstered the accelerated process of efficiency. Automation triggered by AI design tools, new cap analogues, and much-improved stability and translatability of mRNA are all contributory factors. Synthetic biology techniques are the investment focus within such companies, as they reduce impurities and enhance reproducibility. The most significant benefit of these advances is that they not only improve translatability but also enable developers to scale quickly from preclinical studies to full-scale commercialisation while maintaining quality.
High Production Cost and Technical Complexity Remain Key Constraints
Such enormous potential is restrained, however, by the high and crippling cost of raw materials, enzymes, and GMP-grade infrastructure. High costs are also accounted for by complex synthesis protocols because most of them are characterised by stringent quality control and require cold chain logistics. Apart from that, there are still some technological hurdles, such as yield inconsistency and lessening double-stranded RNA contaminants, which remain to challenge such products. As if to slow down new market entrants and rattle smaller developers, all these factors are coupled with limited expertise and capital intensity.
Harmonization in Regulatory Standardization: Creating Long-term Market Opportunities
The mRNA manufacturing market is currently undergoing a stage of regulatory convergence across the US, Europe, and Asia-Pacific. Agencies such as the EMA and FDA have commenced building such frameworks around standardised analytical methodologies, product validation, and process control in mRNA synthesis. This phenomenon of regulatory harmonisation creates transparency and predictability for developers and suppliers, thus facilitating in making of long-term investments in automated, compliant biomanufacturing systems. Increased clarity is set to catalyse greater innovation and entry of regional players.
Competitive Analysis Feature: Strategic Joint Ventures and R&D Expansion
Today, joint-value research activities within collaborative partnerships between pharmaceutical companies, contract manufacturers, and research institutes are invaluable to the evolution of the industry. Various initiatives are ongoing with regard to joint research and development focusing on extending improvements of purity in reagents, lowering costs of synthesis, and increasing yield levels through innovation in enzyme and plasmid construction technologies. Biotechnology startups driven by innovation are feeding off the power of established giants in bringing a conducive ecosystem for sustainable growth and market maturity.
Attractive Opportunities in the Market
• Emergence of Therapeutic mRNA – Expanding applications in cancer and rare diseases drive custom synthesis demand.
• CDMO Partnership Surge – Vaccine developers leverage CDMO agility to meet stringent regulatory milestones.
• Personalised Medicine Acceleration – Micro-batch mRNA manufacturing paves the way for tumour-specific therapies.
• AI-Powered Optimisation – Predictive tools refine synthesis workflows and reduce development timelines.
• Decentralised Biomanufacturing – Modular factories increase regional vaccine independence.
• Next-Gen Delivery Systems – Advances in LNP and polymer-based delivery systems widen mRNA therapeutic viability.
• Cold Chain Innovation – Enhanced cryogenic logistics improve mRNA shelf life and distribution efficiency.
• Standardised Regulatory Pathways – Harmonised guidelines enable cross-border commercialisation of mRNA products.
Report Segmentation
By Raw Material Type:
• Capping Agents (CleanCap Reagents, ARCA, Others)
• Nucleotides
o Modified Nucleic Acids, N1-methylpseudouridine-triphosphate, 5-Methylcytidine triphosphate (5mCTP), Others
o Natural Nucleic Acids (Adenine, Guanine, Cytosine, Uracil)
• Plasmid DNA
• Enzymes (Polymerase, RNase Inhibitor, DNase, Others)
• Others
By Application: Vaccine Production, Therapeutics Production, Others
By End Use: Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Moderna Inc., BioNTech SE, CureVac AG, Thermo Fisher Scientific Inc., Danaher Corporation (Cytiva), GSK plc, Lonza Group AG, Catalent Inc., TriLink BioTechnologies, AGC Biologics.
Report Aspects
• Base Year: 2024
• Historic Years: 2022, 2023, 2024
• Forecast Period: 2025-2035
• Report Pages: 293
Dominating Segments
Nucleotides Segment Leading the Market due to Widespread Incorporation in Synthesis Fidelity and Efficiency
Nucleotides remain the backbone of mRNA synthesis, determining translational accuracy and transcript durability. Modified nucleotides like N1-methylpseudouridine-triphosphate and 5-methylcytidine triphosphate have gained favour because of their greater stability, less activation of the innate immune response, and better optimisation of protein expression levels. The post-pandemic boom in vaccine development has brought a strong upsurge in requests for such high-grade nucleotides. All of them make significant investments in nucleotide purity assurance systems, automated synthesis pipelines, and integrated reagent validation to maintain stringent GMP standards. Their role in both vaccine and therapeutic production streams keeps them at the forefront.
Capping Agents Segment Steps Up Momentum on Technology Advancement and Process Efficiency
5'-Capping methodologies underwent a revolution with the adoption of CleanCap and ARCA analogues, which reduced impurity profiles and simplified process integration crucial element in the translational competency and stability of mRNA transcripts. These agents play a significant role in the maintenance of structural integrity for synthetic mRNA, and thus, they ensure that efficiency is increased in expression and translation in vivo. Participants in the market are shifting towards enzyme-based capping systems that reduce error rates and enhance yields, causing them to increasingly be adopted by preclinical and commercial manufacturing.
Biopharmaceutical & Pharmaceutical Companies Command Major End-Use Share with Developing Therapeutic Pipelines
As mRNA technology moves from vaccines to therapeutics, pharmaceutical companies have consolidated their manufacturing capabilities under their own roof or through partnerships. Modular and single-use manufacturing systems with continuous research and development into RNA stabilisation have enabled these companies to shrink the time-to-market of new candidates. Biopharma giants increasingly adopt automated transcription units and AI-based sequence validation to improve throughput and consistency. Thus, the end-use segment comprises those revenues not only leading but also embedded within the innovation ecosystem for mRNA therapeutics.
Key Takeaways
• Therapeutic Momentum – Clinical adoption of mRNA in oncology and rare diseases expands custom synthesis needs.
• CDMOs Drive Scalability – Contract manufacturing dominates with integrated GMP, analytics, and regulatory services.
• Personalised Therapies Boom – Tumour-specific mRNA products demand agile, micro-scale manufacturing approaches.
• Delivery Platform Innovation – LNP technologies improve intracellular delivery and therapeutic targeting.
• Regional Manufacturing Gaps – Infrastructure deficits in LAMEA spur modular factory deployment.
• Regulatory Alignment Trends – Cross-border frameworks ease product approval and reduce redundancy.
• Cold Chain Complexity – Cryogenic logistics play a pivotal role in maintaining product viability.
• Digital GMP Labs – AI-enabled QA/QC automation enhances reliability and batch traceability.
• Research Support Expands – Custom synthesis providers empower academic and preclinical drug developers.
• Strategic Collaborations Surge – Industry partnerships accelerate pipeline advancement and reduce the cost of development.
Regional Insights
North America fortifies its leadership through progressive manufacturing infrastructure and prudent investments.
North America remains the leading market in the synthesis and production of global mRNA, and the strength of its biopharmaceutical market and its enormous R&D infrastructure make the difference. Especially in the United States, the companies are well innovated for the most part in the areas of enzymatic transcription, automated production platforms, and lipid nanoparticle integration. At the government level, from BARDA through funding programs under the auspices of vaccine resilience and the CHIPS & Science Act, linkages between biotech and academia have matured. That prepared the region for next-generation vaccine and therapeutic manufacturing, all while Canada's emerging biomanufacturing hubs are continuing to increase capacity for small-batch synthesis.
Europe Strengthens Pioneer Position in Sustainable and Regulatory-Compliant Manufacturing
Such is Europe, leading bioprocess sustainable innovation supported by a very strong regulatory ecosystem through the EMA and the EU Commission. In countries like Germany, France, and the Netherlands, circularity in biomanufacturing with less waste is integrated by enzymatic synthesis within their ecosystem. Combined with investment in green biochemistry, the region's sustainability has fast-tracked the standardisation of the GMP framework for mRNA production. Combining European research consortia partnerships with biotech start-ups has been the engine of innovation for high-fidelity synthesis reagents.
Asia-Pacific is Set to Become a Growing Market with Increasing Biopharma Infrastructure
Asia-Pacific is showing the most explosive growth, primarily due to the leading development of pharmaceutical companies in China, India, South Korea, and Japan. Increased vaccine research, national government funding in biotechnology, and investments in local mRNA manufacturing hubs-creating all-time favourable conditions for regional players. The establishment of public-private partnership initiatives like India's Mission mRNA and domestic RNA vaccine initiatives in China indicates the strategic aspiration of the region in localisation and less import dependency.
LAMEA Market Gains Speed through Vaccine Sovereignty at the Regional Level and Strategic Partnerships
LAMEA countries are emerging as important players in the global mRNA ecosystem through specific investments directed towards the corresponding capacity for regional manufacture. Brazil and the UAE have already entered partnerships with European and North American biotechs to set up GMP-certified facilities, thus improving the region's self-reliance on vaccines. The Vision 2030 agenda of Saudi Arabia places biotechnology innovation as its centrepiece, paving a robust ground from which RNA medical research may evolve. Despite infrastructural challenges being evidently palpable, however, long-term strategic partnerships being forged in the region are laying a firm foundation for being continued players in the future market.
Core Strategic Questions Answered in This Report
Q. What is the expected growth trajectory of the mRNA synthesis & manufacturing market from 2024 to 2035?
The global mRNA synthesis & manufacturing market is projected to grow from USD 859.4 million in 2024 to USD 969.30 million by 2035, reflecting a modest CAGR of 1.1% during the forecast period. This growth reflects the transition from pandemic-era mass vaccine production to precision-driven therapeutic applications.
Q. Which key factors are fuelling the growth of the mRNA synthesis & manufacturing market?
Several factors are catalysing growth: the expanding pipeline of mRNA-based therapeutics, rising demand for flexible CDMO support, increasing public and private investment in decentralised manufacturing, technological advancements in LNP delivery systems, and growing global harmonisation of regulatory requirements.
Q. What are the primary challenges hindering the growth of the mRNA synthesis & manufacturing market?
Key challenges include uneven global manufacturing capacity, high cold chain and operational costs, regulatory complexities for personalised therapies, talent shortages in specialised GMP roles, and limited access to scalable technologies in emerging markets.
Q. Which regions currently lead the mRNA synthesis & manufacturing market in terms of market share?
North America leads the market, followed by Europe. The U.S. and Germany are particularly dominant due to established infrastructure, leading CDMOs, and proactive regulatory environments. Asia-Pacific is quickly emerging as a high-growth region with increasing production autonomy.
Q. What emerging opportunities are anticipated in the mRNA synthesis & manufacturing market?
Opportunities include the proliferation of personalised mRNA therapies, rapid advances in AI-assisted production, decentralised biomanufacturing hubs in emerging markets, and increased demand for next-gen delivery technologies that expand the therapeutic reach of mRNA molecules.
Key Benefits for Stakeholders
• The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
• The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
• Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
• A detailed examination of market segmentation helps identify existing and emerging opportunities.
• Key countries within each region are analysed based on their revenue contributions to the overall market.
• The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
• The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.

Chapter 1. Market Snapshot

1.1. Market Definition & Report Overview
1.2. Market Segmentation
1.3. Key Takeaways
1.3.1. Top Investment Pockets
1.3.2. Top Winning Strategies
1.3.3. Market Indicators Analysis
1.3.4. Top Impacting Factors
1.4. Industry Ecosystem Analysis
1.4.1. 360’ Analysis

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4 Market Attractiveness Analysis (top leader’s point of view on market)
2.5.key Findings

Chapter 3. Research Methodology

3.1 Research Objective
3.2 Supply Side Analysis
3.1.1. Primary Research
3.1.2. Secondary Research
3.3 Demand Side Analysis
3.1.3. Primary Research
3.1.4. Secondary Research
3.2. Forecasting Models
3.2.1. Assumptions
3.2.2. Forecasts Parameters
3.3. Competitive breakdown
3.3.1. Market Positioning
3.3.2. Competitive Strength
3.4. Scope of the Study
3.4.1. Research Assumption
3.4.2. Inclusion & Exclusion
3.4.3. Limitations

Chapter 4. Industry Landscape

4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Porter’s 5 Forces Model
4.2.1. Bargaining Power of Buyer
4.2.2. Bargaining Power of Supplier
4.2.3. Threat of New Entrants
4.2.4. Threat of Substitutes
4.2.5. Competitive Rivalry
4.3. Value Chain Analysis
4.4. PESTEL Analysis
4.5. Pricing Analysis and Trends
4.6. Key growth factors and trends analysis
4.7. Market Share Analysis (2025)
4.8. Top Winning Strategies (2025)
4.9. Trade Data Analysis (Import Export)
4.10. Regulatory Guidelines
4.11. Historical Data Analysis
4.12. Analyst Recommendation & Conclusion

Chapter 5. Global MRNA Synthesis & Manufacturing Market Size & Forecasts by Type of 2025-2035

5.1. Market Overview
5.1.1. Market Size and Forecast By Type of 2025-2035
5.2. Capping Agents
5.2.1. CleanCap Reagents
5.2.2. ARCA (Anti-Reverse Cap Analog)
5.2.3. Others
5.3. Nucleotides
5.3.1. Modified Nucleic Acids
5.3.1.1. N1-methylpseudouridine-triphosphate
5.3.1.2. 5-Methylcytidine triphosphate (5mCTP)
5.3.1.3. Others
5.3.2. Natural Nucleic Acids
5.3.2.1. Adenine
5.3.2.2. Guanine
5.3.2.3. Cytosine
5.3.2.4. Uracil
5.4. Plasmid DNA
5.4.1. Market definition, current market trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2025-2035
5.4.3. Market share analysis, by country, 2025-2035
5.5. Enzymes
5.5.1. Polymerase
5.5.2. RNase Inhibitor
5.5.3. DNase
5.5.4. Others
5.6. Others
5.6.1. Market definition, current market trends, growth factors, and opportunities
5.6.2. Market size analysis, by region, 2025-2035
5.6.3. Market share analysis, by country, 2025-2035

Chapter 6. Global MRNA Synthesis & Manufacturing Market Size & Forecasts by Application 2025-2035

6.1. Market Overview
6.1.1. Market Size and Forecast By Application 2025-2035
6.2. Vaccine Production
6.2.1. Market definition, current market trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2025-2035
6.2.3. Market share analysis, by country, 2025-2035
6.3. Therapeutics Production
6.3.1. Market definition, current market trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2025-2035
6.3.3. Market share analysis, by country, 2025-2035
6.4. Others
6.4.1. Market definition, current market trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2025-2035
6.4.3. Market share analysis, by country, 2025-2035

Chapter 7. Global MRNA Synthesis & Manufacturing Market Size & Forecasts by End Use 2025-2035

7.1. Market Overview
7.1.1. Market Size and Forecast By End Use 2025-2035
7.2. Biopharmaceutical & Pharmaceutical Companies
7.2.1. Market definition, current market trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2025-2035
7.2.3. Market share analysis, by country, 2025-2035
7.3. CROs & CMOs
7.3.1. Market definition, current market trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2025-2035
7.3.3. Market share analysis, by country, 2025-2035
7.4. Academic & Research Institutes
7.4.1. Market definition, current market trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2025-2035
7.4.3. Market share analysis, by country, 2025-2035

Chapter 8. Global MRNA Synthesis & Manufacturing Market Size & Forecasts by Region 2025–2035

8.1. Regional Overview 2025-2035
8.2. Top Leading and Emerging Nations
8.3. North America MRNA Synthesis & Manufacturing Market
8.3.1. U.S. MRNA Synthesis & Manufacturing Market
8.3.1.1. Type breakdown size & forecasts, 2025-2035
8.3.1.2. Application breakdown size & forecasts, 2025-2035
8.3.1.3. End Use breakdown size & forecasts, 2025-2035
8.3.2. Canada MRNA Synthesis & Manufacturing Market
8.3.2.1. Type breakdown size & forecasts, 2025-2035
8.3.2.2. Application breakdown size & forecasts, 2025-2035
8.3.2.3. End Use breakdown size & forecasts, 2025-2035
8.3.3. Mexico MRNA Synthesis & Manufacturing Market
8.3.3.1. Type breakdown size & forecasts, 2025-2035
8.3.3.2. Application breakdown size & forecasts, 2025-2035
8.3.3.3. End Use breakdown size & forecasts, 2025-2035
8.4. Europe MRNA Synthesis & Manufacturing Market
8.4.1. UK MRNA Synthesis & Manufacturing Market
8.4.1.1. Type breakdown size & forecasts, 2025-2035
8.4.1.2. Application breakdown size & forecasts, 2025-2035
8.4.1.3. End Use breakdown size & forecasts, 2025-2035
8.4.2. Germany MRNA Synthesis & Manufacturing Market
8.4.2.1. Type breakdown size & forecasts, 2025-2035
8.4.2.2. Application breakdown size & forecasts, 2025-2035
8.4.2.3. End Use breakdown size & forecasts, 2025-2035
8.4.3. France MRNA Synthesis & Manufacturing Market
8.4.3.1. Type breakdown size & forecasts, 2025-2035
8.4.3.2. Application breakdown size & forecasts, 2025-2035
8.4.3.3. End Use breakdown size & forecasts, 2025-2035
8.4.4. Spain MRNA Synthesis & Manufacturing Market
8.4.4.1. Type breakdown size & forecasts, 2025-2035
8.4.4.2. Application breakdown size & forecasts, 2025-2035
8.4.4.3. End Use breakdown size & forecasts, 2025-2035
8.4.5. Italy MRNA Synthesis & Manufacturing Market
8.4.5.1. Type breakdown size & forecasts, 2025-2035
8.4.5.2. Application breakdown size & forecasts, 2025-2035
8.4.5.3. End Use breakdown size & forecasts, 2025-2035
8.4.6. Rest of Europe MRNA Synthesis & Manufacturing Market
8.4.6.1. Type breakdown size & forecasts, 2025-2035
8.4.6.2. Application breakdown size & forecasts, 2025-2035
8.4.6.3. End Use breakdown size & forecasts, 2025-2035
8.5. Asia Pacific MRNA Synthesis & Manufacturing Market
8.5.1. China MRNA Synthesis & Manufacturing Market
8.5.1.1. Type breakdown size & forecasts, 2025-2035
8.5.1.2. Application breakdown size & forecasts, 2025-2035
8.5.1.3. End Use breakdown size & forecasts, 2025-2035
8.5.2. India MRNA Synthesis & Manufacturing Market
8.5.2.1. Type breakdown size & forecasts, 2025-2035
8.5.2.2. Application breakdown size & forecasts, 2025-2035
8.5.2.3. End Use breakdown size & forecasts, 2025-2035
8.5.3. Japan MRNA Synthesis & Manufacturing Market
8.5.3.1. Type breakdown size & forecasts, 2025-2035
8.5.3.2. Application breakdown size & forecasts, 2025-2035
8.5.3.3. End Use breakdown size & forecasts, 2025-2035
8.5.4. Australia MRNA Synthesis & Manufacturing Market
8.5.4.1. Type breakdown size & forecasts, 2025-2035
8.5.4.2. Application breakdown size & forecasts, 2025-2035
8.5.4.3. End Use breakdown size & forecasts, 2025-2035
8.5.5. South Korea MRNA Synthesis & Manufacturing Market
8.5.5.1. Type breakdown size & forecasts, 2025-2035
8.5.5.2. Application breakdown size & forecasts, 2025-2035
8.5.5.3. End Use breakdown size & forecasts, 2025-2035
8.5.6. Rest of APAC MRNA Synthesis & Manufacturing Market
8.5.6.1. Type breakdown size & forecasts, 2025-2035
8.5.6.2. Application breakdown size & forecasts, 2025-2035
8.5.6.3. End Use breakdown size & forecasts, 2025-2035
8.6. LAMEA MRNA Synthesis & Manufacturing Market
8.6.1. Brazil MRNA Synthesis & Manufacturing Market
8.6.1.1. Type breakdown size & forecasts, 2025-2035
8.6.1.2. Application breakdown size & forecasts, 2025-2035
8.6.1.3. End Use breakdown size & forecasts, 2025-2035
8.6.2. Argentina MRNA Synthesis & Manufacturing Market
8.6.2.1. Type breakdown size & forecasts, 2025-2035
8.6.2.2. Application breakdown size & forecasts, 2025-2035
8.6.2.3. End Use breakdown size & forecasts, 2025-2035
8.6.3. UAE MRNA Synthesis & Manufacturing Market
8.6.3.1. Type breakdown size & forecasts, 2025-2035
8.6.3.2. Application breakdown size & forecasts, 2025-2035
8.6.3.3. End Use breakdown size & forecasts, 2025-2035
8.6.4. Saudi Arabia (KSA MRNA Synthesis & Manufacturing Market
8.6.4.1. Type breakdown size & forecasts, 2025-2035
8.6.4.2. Application breakdown size & forecasts, 2025-2035
8.6.4.3. End Use breakdown size & forecasts, 2025-2035
8.6.5. Africa MRNA Synthesis & Manufacturing Market
8.6.5.1. Type breakdown size & forecasts, 2025-2035
8.6.5.2. Application breakdown size & forecasts, 2025-2035
8.6.5.3. End Use breakdown size & forecasts, 2025-2035
8.6.6. Rest of LAMEA MRNA Synthesis & Manufacturing Market
8.6.6.1. Type breakdown size & forecasts, 2025-2035
8.6.6.2. Application breakdown size & forecasts, 2025-2035
8.6.6.3. End Use breakdown size & forecasts, 2025-2035

Chapter 9. Company Profiles

9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. AubinGroup
9.2.1.1. Company Overview
9.2.1.2. Key Executives
9.2.1.3. Company Snapshot
9.2.1.4. Financial Performance (Subject to Data Availability)
9.2.1.5. Product/Services Port
9.2.1.6. Recent Development
9.2.1.7. Market Strategies
9.2.1.8. SWOT Analysis
9.2.2. BioNTech SE,
9.2.3. CureVac AG
9.2.4. Thermo Fisher Scientific Inc.
9.2.5. Danaher Corporation (Cytiva)
9.2.6. GSK plc
9.2.7. Lonza Group AG
9.2.8. Catalent Inc.
9.2.9. TriLink BioTechnologies
9.2.10. AGC Biologics.